| Literature DB >> 32265717 |
Qi Ge1,2, Liang Chen2, Yi Yuan2,3, Lanlan Liu2, Fan Feng4, Peng Lv2, Shangshang Ma2,3, Keping Chen2, Qin Yao1,2.
Abstract
Diabetes mellitus (DM) is a chronic inflammatory disease, and the rapidly increasing DM is becoming a major problem of global public health. Traditional Chinese medicine (TCM) has a long history of treating diabetes. It has been developed and utilized because of its good efficacy and no toxic side effects. Lobelia chinensis is a traditional whole grass herbal. With the continuous deepening of pharmacological research on TCM, the active ingredients of L. chinensis are continuously revealed, which contained the alkaloids, flavonoids, flavonoid glycosides and amino acids that have the good effects of anti-inflammatory, anti-viral and anti-diabetic. In order to further explore the targets of active ingredients and its anti-diabetic mechanism, a feasible network pharmacology analysis model based on chemical, pharmacokinetic and pharmacological data was developed by network construction method to clarify the anti-diabetic mechanism of L. chinensis. The present study conducted by gas chromatography-mass spectrometer (GC/MS), which identified 208 metabolites of L. chinensis, of which 23 ingredients may have effective pharmacological effects after absorption, distribution, metabolism, and excretion (ADME) screening. Network pharmacological analysis on the active ingredients revealed that 5-hydroxymethylfurfural in L. chinensis affects the insulin resistance signaling pathway by acting on GSK3B, TNF, and MAPK1, acacetin affects the diabetic pathway by acting on INSR, DPP4, and GSK3B, that regulate type 2 diabetes, non-insulin-dependent DM, and inflammatory diseases. These results successfully indicated the potential anti-diabetic mechanism of the active ingredients of L. chinensis.Entities:
Keywords: Lobelia chinensis; active ingredients; anti-diabetic; anti-inflammatory; network pharmacology
Year: 2020 PMID: 32265717 PMCID: PMC7099657 DOI: 10.3389/fphar.2020.00347
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1The flowchart of the network pharmacological analysis approach.
The concentration of the active ingredients of Lobelia chinensis.
| MOL ID | Ingredients | Concentration |
|---|---|---|
| MOL012231 | Leptodactylone | 23.58 mg/g |
| MOL012207 | Lobelanidine | 12.62 mg/g |
| MOL001689 | Acacetin | 4.78 mg/g |
| MOL012216 | Norlobelanine | 6.05 mg/g |
| MOL001999 | Scoparone | 0.13 mg/g |
| MOL005928 | Isoferulic acid | 22.77 mg/g |
| MOL012209 | 2-[(2R,6S)-6-[(2R)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone (Lobelin) | 46.60 mg/g |
| MOL009009 | (+)-Medioresinol | 0.84 mg/g |
| MOL004678 | Limetin | 2.51 mg/g |
| MOL012208 | Lobelanine | 27.88 mg/g |
| MOL002341 | Hesperetin | 3.27 mg/g |
| MOL000748 | 5-Hydroxymethylfurfural (HMF) | 1.26 mg/g |
| MOL000103 | 4-Oxoniobenzoate (PHB) | 5.49 mg/g |
Ingredients information of Lobelia chinensis.
| MOL ID | Name | Molecular Formula | CAS No. | MW (g/mol) | OB% | BBB | DL | HL | Structural Formula |
|---|---|---|---|---|---|---|---|---|---|
| MOL012207 | Lobelanidine | N/A | 552-72-7 | 339.52 | 60.53 | 0.31 | 0.32 | 5.78 |
|
| MOL012208 | Lobelanine | C22H25NO2 | 579-21-5 | 335.48 | 54.13 | 0.46 | 0.32 | 31.96 |
|
| MOL000103 | 4-Oxoniobenzoate (PHB) | C7H6O3 | 99-96-7 | 138.13 | 30.15 | 0.21 | 0.03 | 11.77 |
|
| MOL012209 | 2-[(2R,6S)-6-[(2R)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone (Lobelin) | C22H27NO2 | 90-69-7 | 337.50 | 45.53 | 0.22 | 0.32 | 19.19 |
|
| MOL011678 | (3S,8S,9S,10R,13R,14S,17R)-17-[(1S,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | C29H50O | 474-58-8 | 414.79 | 36.91 | 1.15 | 0.75 | 4.93 |
|
| MOL012215 | Propanol (POL) | C3H8O | 71-23-8 | 60.11 | 72.69 | 0.97 | 0.00 | 11.62 |
|
| MOL012216 | Norlobelanine | C21H23NO2 | 6035-31-0 | 321.45 | 64.08 | 0.33 | 0.30 | 35.32 |
|
| MOL012217 | Phytenal | N/A | 13754-69-3 | 294.58 | 35.22 | 1.41 | 0.14 | 3.96 |
|
| MOL012221 | Trans-10-ethyl-8-methyl-lobelidiol | N/A | N/A | 229.41 | 33.93 | -0.04 | 0.07 | 2.73 |
|
| MOL012223 | Trans-N-methyl-2,6-bis(2-hydroxybutyl)-△3-piperideine | N/A | N/A | 243.44 | 42.40 | -0.19 | 0.08 | 4.73 |
|
| MOL012231 | Leptodactylone | C11H10O5 | 61899-44-3 | 222.21 | 37.56 | 0.22 | 0.10 | 2.68 |
|
| MOL001999 | Scoparone | C11H10O4 | 120-08-1 | 206.21 | 74.75 | 0.46 | 0.09 | 0.73 |
|
| MOL002341 | Hesperetin | C16H14O6 | 520-33-2 | 302.30 | 70.31 | -0.25 | 0.27 | 15.78 |
|
| MOL004678 | Limetin | C11H10O4 | 487-06-9 | 206.21 | 36.63 | 0.47 | 0.09 | 1.33 |
|
| MOL005928 | Isoferulic acid | C10H10O4 | 537-73-5 | 194.20 | 50.83 | 0.01 | 0.06 | 2.45 |
|
| MOL007170 | Cirsiumaldehyde | C12H10O5 | 7389-38-0 | 234.22 | 41.38 | 0.03 | 0.11 | 7.81 |
|
| MOL000748 | 5-Hydroxymethylfurfural (HMF) | C6H6O3 | 76330-16-0 | 126.12 | 45.07 | -0.27 | 0.02 | 11.73 |
|
| MOL009009 | (+)-Medioresinol | N/A | 40957-99-1 | 388.45 | 87.19 | -0.29 | 0.62 | 1.39 |
|
| MOL012232 | 5-Hydroxy-6,7-dimethoxycoumarin | C11H10O5 | 28449-62-9 | 222.21 | 67.31 | 0.20 | 0.10 | 1.83 |
|
| MOL009653 | Cycloeucalenol | N/A | 469-39-6 | 426.80 | 39.73 | 1.04 | 0.79 | 5.01 |
|
| MOL001504 | (E,7R,11S)-3,7,11,15-tetramethylhexadec-2-en-1-ol | C20H40O | 150-86-7 | 296.60 | 33.82 | 0.90 | 0.13 | 3.46 |
|
| MOL001689 | Acacetin | C16H12O5 | 480-44-4 | 284.28 | 34.97 | -0.05 | 0.24 | 17.25 |
|
| MOL004688 | Cumic acid | C10H12O2 | 536-66-3 | 164.22 | 45.78 | 1.10 | 0.04 | -3.13 |
|
Figure 2Lobelia chinensis ingredients–target interaction network. The pink triangle represent the 13 bioactive ingredients, and the blue circle represent the 80 target proteins.
Figure 3Protein–protein interaction (PPI) network analysis.
Figure 4Gene Ontology (GO) enrichment analysis of the target proteins. Biological process (green), molecular function (purple), and cellular component (blue) accounted for 71.47%, 16.67%, and 11.59%, respectively.
Figure 5Targets–pathway interaction analysis (A) and KEGG analysis of target proteins (B). The red ellipse represent the target proteins, and the green diamond represent the pathways.
Figure 6Distribution of the target proteins of Lobelia chinensis on the predicted pathway. The orange nodes are potential target proteins of L. chinensis, while the blue nodes are relevant targets in the pathway.